

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT5021835

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
YANGMEI LI	05/09/2016
RICHARD A. HOUGHTEN	05/09/2016
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	TORREY PINES INSTITUTE FOR MOLECULAR STUDIES
<b>Street Address:</b>	11350 SW VILLAGE PARKWAY
<b>City:</b>	PORT ST. LUCIE
<b>State/Country:</b>	FLORIDA
<b>Postal Code:</b>	34987
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	15568931
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(404)645-7707
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	4046457700
<b>Email:</b>	athomason@mcciplaw.com
<b>Correspondent Name:</b>	MEUNIER CARLIN & CURFMAN LLC
<b>Address Line 1:</b>	999 PEACHTREE STREET, NE
<b>Address Line 2:</b>	SUITE 1300
<b>Address Line 4:</b>	ATLANTA, GEORGIA 30309
<b>ATTORNEY DOCKET NUMBER:</b>	10110-120US1
<b>NAME OF SUBMITTER:</b>	CHRISTOPHER L. CURFMAN
<b>SIGNATURE:</b>	/Christopher L. Curfman/
<b>DATE SIGNED:</b>	06/25/2018
<b>Total Attachments: 3</b>	
source=10110-120US1 Assignment (TP)#page1.tif	
source=10110-120US1 Assignment (TP)#page2.tif	
source=10110-120US1 Assignment (TP)#page3.tif	

ASSIGNMENT

For valuable consideration, we, **Yangmei Li** and **Richard A. Houghten**, both of Port St. Lucie, Florida, hereby assign to TORREY PINES INSTITUTE FOR MOLECULAR STUDIES, a Florida non-profit corporation, having a place of business at 11350 SW Village Parkway, Port St. Lucie, FL 34987, and its successors and assigns (collectively hereinafter "the Assignee"), the entire right, title, and interest throughout the world in the inventions and improvements that are subject of International Patent Application PCT/US2016/029180, titled "MUTANT KRAS INHIBITORS," filed April 25, 2016, which claims priority to Provisional U.S. Patent Application No. 62/152,333, titled "MUTANT KRAS INHIBITORS," and filed April 24, 2015; this assignment including said application, any and all divisional, continuing, substitute, renewal, reissue and all other applications for patent that have been or shall be filed in the United States and all foreign countries on any such inventions or improvements; all original and reissued patents that have been or shall be issued in the United States and all foreign countries on such inventions or improvements; and all United States and foreign patents, utility models, and design registrations granted for any of said inventions or improvements, and the right to claim priority based on the filing date of said application under the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent Convention, and all other treaties of like purposes; and we authorize the Assignee to apply in all countries in our names or in its own name for patents, utility models, design registrations and like rights of exclusion and for inventors' certificates for said inventions and improvements; and we agree for ourselves and our respective heirs, legal representatives and assigns, without further compensation to perform such lawful acts and to sign such further applications, assignments, Preliminary Statements and other lawful documents as the Assignee may reasonably request to effectuate fully this assignment.



